Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A [Phase 3]

View source ↗

Summary

A Phase 3 trial of valoctocogene roxaparvovec in Hemophilia A with prophylactic steroids has completed and posted results (status COMPLETED) in April 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Roctavian (valoctocogene roxaparvovec)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2024-04-04